STUDY DESIGN: This is a secondary analysis of a randomized controlled trial, the Twin Birth Study (TBS). In TBS, women with diamniotic twins with a cephalic presenting twin between 32 0/7 and 38 6/7 weeks gestation were randomized to planned vaginal or cesarean delivery. In this secondary analysis, women attempting vaginal birth of twins were analyzed. We performed a retrospective case-control study, according to success (vaginal delivery of both twins) or failure (cesarean of one or both twins) of twin vaginal delivery. Maternal and fetal characteristics prior to labor were evaluated in order to identify variables significantly associated with success or failure of twin vaginal birth. Logistic regression was used to create a prediction model that was validated against a training set. RESULTS: 1124 patients attempting a trial of vaginal delivery of twins were analyzed. 783 (70%) successfully delivered vaginally, and 341 (30%)had a cesarean of one or both twins. Pre-labor characteristics significantly associated with delivery route were: maternal age, parity, history of prior cesarean delivery, and presentation of the second twin. Using these characteristics, a predictive model was developed. An ROC curve was developed to assess accuracy with an AUC of 0.6 (Figure 1 
OBJECTIVE: Prophylactic antibiotics are indicated in Preterm Premature
Rupture of Membranes (PROM) to prolong latency and to reduce the risk of both neonatal and maternal infections. Macrolides are usually given with penicillin based on their activity against the major pelvic pathogens. We aimed to compare outcomes between two different macrolides: Roxithromycin which is given twice a day for a week and Azithromycin given as a single dose and therefore more convenient STUDY DESIGN: Inclusion criteria were: a singletone pregnancy, 24-34 weeks of gestation, preterm PROM. All were treated with penicillin and macrolides: Roxithromycin between July 2005 and May 2016, and Azithromycin between May 2016 and May 2018 based on local protocol changes during those two periods of time. The primary outcome was the length of latency period, defined as time from first antibiotic dose to 34+0 weeks or spontaneous or indicated delivery prior to 34+0 weeks. Secondary outcomes were rates of chorioamnionitis, mode of delivery, birth weight and Apgar scores RESULTS: Of 207 women who met inclusion criteria, 173 received Penicillin and Roxithromycin and 34 received Penicillin and Azithromycin. Baseline characteristics were the same in the two groups. The latency period was longer in the Azithromycin group in compare with the Roxithromycin group (14.09 days and 7.87 days respectively, p¼0.003). There was no difference in the rate of chorioamnionitis, the rate of cesarean delivery, Apgar scores and birth weights between the groups CONCLUSION: Among women with preterm PROM between 24 and 34 completed weeks, Azithromycin compared to Roxithromycin is related with longer latency period.
Given its more convenient regimen it is justified to be chosen as the first line treatment for preterm PROM patients 173 Pharmacodynamics of tranexamic acid use for hemorrhage prevention at cesarean delivery OBJECTIVE: To determine the pharmacodynamic profile of tranexamic acid (TXA) given at cesarean delivery using rotational thromboelastometry. We expected that as the drug was cleared metabolically, it would be less likely to reverse the ex vivo effect of tissue plasminogen activator (tPA). STUDY DESIGN: We administered 5mg/kg of intravenous tranexamic acid to pregnant women at the time of umbilical cord clamp. Blood samples were collected prior to delivery, after administration within 10 minutes, 30-60 minutes, 1.5-3 hours, 4-6 hours, 7-8 hours and 24 hours. We performed rotational thromboelastometry using EXTEM, APTEM and EXTEM with spiked tPA serially. Inclusion criteria included > 34 weeks gestation, normal renal function and scheduled cesarean delivery. Women were excluded if they had a history of thrombophilia or were on anticoagulation. Our primary outcome was maximum lysis (ML) at 60 minutes in EXTEM samples with tPA over time. We also looked at maximum clot firmness (MCF) prior to and immediately after drug administration. RESULTS: We included 10 women in our study and 9 completed all blood draws. Women were on average 33 AE 4.7 years old, 38 weeks (range 34-39) in gestation and had a body mass index (BMI) of 33.2 AE 7.2 kg/m 2 . ML values for EXTEM with tPA over time are included (Table) . The average ML and standard deviation (SD) are 99.7% (SD 0.5) for pre-delivery and 4.9% (1.8), 14.8% (11.1), 49.9% (35.3), 79.9% (22.7), 86.9% (25.1), 88.3% (31.7) for each corresponding serial blood draw as detailed above. A representative sample of assays over time is included (Figure) . MCF for pre-delivery, 73 AE 3.6 mm, and within 10 minutes of drug administration, 70 AE 6.3 mm, was not different (p¼0.19). CONCLUSION: The effects of tranexamic acid given in vivo appears to reverse the added ex vivo tPA until about 7-8 hours after administration, though there is some variability in drug clearance. There does not appear to be evidence of hypercoagulability by rotational thromboelastometry after TXA administration.
